Company’s 36-month beta value is 0.19.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EWTX is 59.21M, and currently, short sellers hold a 15.77% ratio of that floaft. The average trading volume of EWTX on October 25, 2024 was 1.21M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has dropped by -0.55 in relation to previous closing price of 34.81. Nevertheless, the company has seen a loss of -2.51% in its stock price over the last five trading days. benzinga.com reported 2024-09-30 that Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
EWTX’s Market Performance
EWTX’s stock has fallen by -2.51% in the past week, with a monthly rise of 33.82% and a quarterly rise of 82.40%. The volatility ratio for the week is 3.93% while the volatility levels for the last 30 days are 5.20% for Edgewise Therapeutics Inc. The simple moving average for the past 20 days is 11.62% for EWTX’s stock, with a 80.03% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Piper Sandler repeating the rating for EWTX by listing it as a “Overweight.” The predicted price for EWTX in the upcoming period, according to Piper Sandler is $48 based on the research report published on March 07, 2024 of the current year 2024.
Goldman gave a rating of “Sell” to EWTX, setting the target price at $5 in the report published on August 25th of the previous year.
EWTX Trading at 41.07% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.56% of loss for the given period.
Volatility was left at 5.20%, however, over the last 30 days, the volatility rate increased by 3.93%, as shares surge +33.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +103.05% upper at present.
During the last 5 trading sessions, EWTX fell by -2.51%, which changed the moving average for the period of 200-days by +213.30% in comparison to the 20-day moving average, which settled at $31.02. In addition, Edgewise Therapeutics Inc saw 216.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 75,000 shares at the price of $28.27 back on Sep 20 ’24. After this action, Russell Alan J now owns 12,719 shares of Edgewise Therapeutics Inc, valued at $2,120,101 using the latest closing price.
MOORE JOHN R, the General Counsel of Edgewise Therapeutics Inc, sale 50,000 shares at $28.37 during a trade that took place back on Sep 20 ’24, which means that MOORE JOHN R is holding 3,252 shares at $1,418,510 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -60.47 for the present operating margin
- 0.09 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -51.46. The total capital return value is set at -0.26. Equity return is now at value -28.20, with -26.88 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.78. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -43.83.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1424.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.24.
Conclusion
In a nutshell, Edgewise Therapeutics Inc (EWTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
